PMID- 30177103
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20181105
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 50
IP  - 7
DP  - 2018 Sep
TI  - Effect of Successful Treatment of Hepatitis C Virus Infection Recurrence With
      Direct-Acting Antiviral Agents on Physical Performance in Liver Transplant
      Recipients.
PG  - 2027-2030
LID - S0041-1345(18)30296-3 [pii]
LID - 10.1016/j.transproceed.2018.02.109 [doi]
AB  - BACKGROUND: Hepatitis C virus (HCV) infection deregulates function of many organs
      and systems, affecting patient's daily functioning. The results of treatment of
      HCV infection recurrence after liver transplantation have improved significantly 
      as a result of the introduction of direct-acting antiviral agents (DAA). This
      study was aimed at prospective assessment of the effect of HCV elimination with
      DAA on physical performance of liver transplant recipients. METHODS: Eight women 
      and 21 men, median age 61.3 (range, 20.1-71.5) years, participated in the study. 
      Assessment of serum total bilirubin, alanine and aspartate aminotransferase,
      muscle strength, body composition, and 6-minute walk test (6MWT) were performed
      before treatment and 12 weeks after the end of the treatment period. RESULTS: In 
      the 6MWT test we observed significant subjective (dyspnea: 58.3% pretreatment vs 
      27.6% posttreatment, P = .018; fatigue: 96.6% pretreatment vs 51.7%
      posttreatment, P = .0001) and objective improvement (distance: 415.4 meters
      pretreatment vs 505.2 meters posttreatment, P < .0000001). We did not observe an 
      increase in muscle mass nor improvement in blood biochemical parameters.
      CONCLUSION: A significant objective and subjective improvement in physical
      performance was seen in liver transplant recipients after successful treatment of
      HCV infection with DAA.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Wojtowicz, M
AU  - Wojtowicz M
AD  - Department of Immunology, Transplant Medicine and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Wilkowski, P
AU  - Wilkowski P
AD  - Department of Immunology, Transplant Medicine and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Hryniewiecka, E
AU  - Hryniewiecka E
AD  - Department of Immunology, Transplant Medicine and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland; Department of Clinical Nursing, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Cieciura, T
AU  - Cieciura T
AD  - Department of Immunology, Transplant Medicine and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Paczek, L
AU  - Paczek L
AD  - Department of Immunology, Transplant Medicine and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland; Department of Bioinformatics, Institute of 
      Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
FAU - Ciszek, M
AU  - Ciszek M
AD  - Department of Immunology, Transplant Medicine and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland. Electronic address: mciszek@net.pl.
LA  - eng
PT  - Journal Article
DEP - 20180313
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*therapeutic use
MH  - Female
MH  - Hepacivirus/drug effects
MH  - Hepatitis C/*complications/*drug therapy
MH  - Humans
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Recurrence
MH  - Young Adult
EDAT- 2018/09/05 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/09/05 06:00
PHST- 2017/12/25 00:00 [received]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2018/09/05 06:00 [entrez]
PHST- 2018/09/05 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
AID - S0041-1345(18)30296-3 [pii]
AID - 10.1016/j.transproceed.2018.02.109 [doi]
PST - ppublish
SO  - Transplant Proc. 2018 Sep;50(7):2027-2030. doi:
      10.1016/j.transproceed.2018.02.109. Epub 2018 Mar 13.